Compare XHR & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XHR | OGN |
|---|---|---|
| Founded | 2007 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | 2014 | 2020 |
| Metric | XHR | OGN |
|---|---|---|
| Price | $16.30 | $8.75 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 5 | 4 |
| Target Price | ★ $13.20 | $11.75 |
| AVG Volume (30 Days) | 507.6K | ★ 5.6M |
| Earning Date | 05-01-2026 | 04-30-2026 |
| Dividend Yield | ★ 3.48% | 0.94% |
| EPS Growth | ★ 326.67 | N/A |
| EPS | 0.64 | ★ 0.72 |
| Revenue | $1,078,500,000.00 | ★ $6,216,000,000.00 |
| Revenue This Year | $4.13 | $0.42 |
| Revenue Next Year | $3.29 | $1.67 |
| P/E Ratio | $25.14 | ★ $11.83 |
| Revenue Growth | ★ 3.80 | N/A |
| 52 Week Low | $9.61 | $5.69 |
| 52 Week High | $16.48 | $13.25 |
| Indicator | XHR | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 68.27 | 70.76 |
| Support Level | $14.26 | $8.32 |
| Resistance Level | $16.35 | $9.79 |
| Average True Range (ATR) | 0.36 | 0.48 |
| MACD | 0.19 | 0.37 |
| Stochastic Oscillator | 98.94 | 91.56 |
Xenia Hotels & Resorts Inc is a real estate investment trust that invests in premium full-service, lifestyle, and urban upscale hotels and resorts across the United States. The company owns and pursues hotels in the upscale, upper upscale, and luxury segments that are affiliated with various brands. Its hotels are operated by Marriott, along with Hilton, Hyatt, Starwood, Kimpton, Aston, Fairmont, and Loews. The firm's properties are located in various regions across the U.S.: the South Atlantic, West South Central, Pacific, Mountain, and other regions. Xenia's revenue is divided between the sale of rooms, food and beverages, and other sources.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.